EscitalopramSerotonin reuptake inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Escitalopram Dilution Calculator
calculate
Escitalopram Molarity Calculator
calculate
Cas No. | 128196-01-0 | SDF | Download SDF |
Chemical Name | (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile | ||
Canonical SMILES | CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F | ||
Formula | C20H21FN2O | M.Wt | 324.39 |
Solubility | Soluble in DMSO | Storage | Store at -20°C |
Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
Escitalopram (Lexapro,Cipralex)is a selective inihibitor of serotonin(5-HT) reuptake (SSRI) with a Ki value of 6.6nM for [3H]-5-HT uptake [1].
Escitalopram is the S-(+)-enantiomer of citalopram and has the inhibition of [3H]-5-HT uptake and [125I]-RTI-55 binding in COS-1 cells expressing the human serotonin transporter (5-HTT) with Ki values of 6.6±1.4nM and 3.9±2.2nM, respectively. In addition, Escitalopram has been reported to inhibit the accumulation of3H-labelled monoamines into rat brain synaptosomes in vitro with IC50 values of 2.1±0.75nM, 2500±202nM and 40000±15500nM for [3H]-5-HT, [3H]-I-NA and [3H]-DA, respectively. Apart from these, Escitalopram has shown the in vitro affinity for rat histamine H1 receptors and the rat sigma σ1 site with Ki values of 1500±780nM and 100±71nM, respectively [1].
References:[1] Sánchez C1, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62. Epub 2003 Apr 26.